|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 39.95 EUR | +0.63% |
|
+3.36% | -29.17% |
| Apr. 25 | Formycon AG Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| Mar. 18 | Formycon, Fresenius Kabi Sign Settlement Deal with Johnson & Johnson for Ustekinumab Biosimilar | MT |
Formycon AG reported earnings results for the half year ended June 30, 2023. For the half year, the company reported sales was EUR 43.79 million compared to EUR 17.64 million a year ago. Net income was EUR 1.8 million compared to EUR 80.03 million a year ago.
Basic earnings per share from continuing operations was EUR 0.114 compared to EUR 6.51 a year ago. Diluted earnings per share from continuing operations was EUR 0.113 compared to EUR 6.41 a year ago.
| 1st Jan change | Capi. | |
|---|---|---|
| -29.17% | 753M | |
| +1.51% | 42.75B | |
| +49.22% | 41.61B | |
| +8.57% | 41.34B | |
| -12.36% | 26.59B | |
| +8.92% | 25.49B | |
| -25.13% | 18.12B | |
| +29.17% | 12.24B | |
| -3.12% | 11.76B | |
| +6.35% | 11B |
FORMYCON AG 
